Tally Levy

Prof. Tally Levy

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2006 in Gynecologic Oncology
Verified
Journal Article
Closed access
PDF file
JMJoseph Menczer
Joseph Menczer
ACAngela Chetrit
Angela Chetrit
SSSiegal Sadetzki
Siegal Sadetzki
AGAbraham Golan
Abraham Golan
TLTally Levy
Tally Levy

2 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
OEOsnat Elyashiv
Osnat Elyashiv
NANatalie Aleohin
Natalie Aleohin
ZMZohar Migdan
Zohar Migdan
SLSophia Leytes
Sophia Leytes
OPOfri Peled
Ofri Peled
TLTally Levy
Tally Levy
Objective: The goal of this study was to evaluate response to treatment and survival in epithelial ovarian cancer patients with acquired secondary platinum resistance (SPR) compared to patients with primary platinum resistance (PPR). Methods: Patients were categorized as PPR (patients with disease recurrence occurring during or <6 months after completing first-line platinum-based chemotherapy) and SPR (patients with previously platinum-sensitive disease that developed platinum resistance on subsequent treatments). Clinico-pathological variables and treatment outcomes were compared. Results: Of the 118 patients included in this study, 60 had PPR and 58 developed SPR. The SPR women had a significantly higher rate of optimal debulking during their upfront and interval operations, significantly lower CA-125 levels during their primary treatment, and a significantly higher complete and partial response rate to primary chemotherapy. Once platinum resistance appeared, no significant difference in survival was observed between the two groups. The median PFS was 2 months in the PPR group and 0.83 months in the SPR group (p = 0.085). Also, no significant difference was found in post-platinum-resistant relapse survival, with a median of 17.63 months in the PPR and 20.26 months in the SPR group (p = 0.515). Conclusions: Platinum resistance is an important prognostic factor in women with EOC. Patients with SPR acquire the same poor treatment outcome as with PPR. There is a great need for future research efforts to discover novel strategies and biological treatments to reverse resistance and improve survival.

1 November 2017 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
OEOsnat Elyashiv
Osnat Elyashiv
RSRon Sagiv
Ron Sagiv
RKRam Kerner
Ram Kerner
RKRan Keidar
Ran Keidar
JMJoseph Menczer
Joseph Menczer
TLTally Levy
Tally Levy

1 May 2020 in Gynecologic Oncology
Verified
Journal Article
Closed access
TLTally Levy
Tally Levy
ZMZ. Migdan
Z. Migdan
NAN. Aleohin
N. Aleohin
BSBen- Shem
Ben- Shem
OPO. Peled
O. Peled
OEO. Elyashiv
O. Elyashiv

23 July 1999 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
AHAnnette Hasenburg
Annette Hasenburg
SLS. C. Ledet
S. C. Ledet
TAT. Ardaman
T. Ardaman
TLTally Levy
Tally Levy
DKD. G. Kieback
D. G. Kieback

16 June 2020 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
OTOri Tal
Ori Tal
HHHadas Ganer Herman
Hadas Ganer Herman
OGOhad Gluck
Ohad Gluck
TLTally Levy
Tally Levy
RRam kerner
Ram kerner
RSRon Sagiv
Ron Sagiv